DÄ internationalArchive18/2009Treatment of Depressive Disorders: In reply

Correspondence

Treatment of Depressive Disorders: In reply

Dtsch Arztebl Int 2009; 106(18): 321-2. DOI: 10.3238/arztebl.2009.0322

Bschor, T

LNSLNS Opipramol is licensed merely for the treatment of generalized anxiety disorders and somatoform disorders. A recommendation for the treatment of depression in the context of our CME certified article is therefore out of the question. We cannot find a general recommendation against tricyclic antidepressants in our article, and this was not our intention anyway. We do not share the recommendation by Leutgeb, to use a combination of two antidepressants for primary treatment, especially in elderly patients.

We thank Müller-Oerlinghausen for his additional points.

We welcome Schulz's mention of the new Cochrane review of St John's wort. As stated in Deutsches Ärzteblatt, our manuscript was submitted in June 2008. The Cochrane review was published in October 2008. We object to any accusation of intentional omission.

We thank Schauenburg for his additional explanations. Our article discusses psychotherapy on nearly 1 1/2 pages, so that we cannot quite understand why he has accused us of sidelining the subject. The figure is a therapeutic algorithm exclusively for somatotherapy of depression. We agree that this should have been made more explicit in the figure legend. Our article discusses the importance of the therapeutic relationship for psychotherapy in more detail in the section entitled "Psychotherapy." The paragraph selected by Waldmann, however, comes from the section entitled "Basic treatment strategy," where we intended to provide a more general overview.

Leichsenring quotes us incorrectly. Our criticism relating to inclusion of patients with different diagnoses (not only depression) in meta-analyses and review articles on psychoanalytical/psychodynamic psychotherapy relates only to his 2005 article, not, as he claims in his reader's letter, his 2001 article. His 2005 review includes—in addition to depressive disorders—anxiety disorders, post-traumatic stress disorders, somatoform disorders, bulimia nervosa and anorexia nervosa, borderline personality disorder and other personality disorders, as well as substance dependence and misuse.
DOI: 10.3238/arztebl.2009.0322


PD Dr. med. Tom Bschor
Jüdisches Krankenhaus Berlin
Abteilung für Psychiatrie und Psychotherapie
Heinz-Galinski-Str. 1
13347 Berlin, Germany
bschor@jkb-online.de

Conflict of interest statement
PD Dr. Bschor has received honoraria for speaking from Sanofi-Aventis, Lilly, Esparma, GlaxoSmithKline, Pfizer, and AstraZeneca. Dr Adli MD has reported research grants from the Federal Ministry of Education and Research and the following companies: Pharmacia, Pfizer, Lilly, Janssen-Cilag, and Wyeth. He has received honoraria from AstraZeneca, Lilly, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, Sanofi-Aventis, Wyeth, and Cyberonics.
1.
Bschor T, Adli M: Treatment of depressive disorders. [Therapie depressiver Erkrankungen.] Dtsch Arztebl Int 2008; 105(45): 782–92.
1. Bschor T, Adli M: Treatment of depressive disorders. [Therapie depressiver Erkrankungen.] Dtsch Arztebl Int 2008; 105(45): 782–92.

Info

Specialities